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1. Introduction 
T cell hybridomas are useful tools for studying antigen-specific cel-
lular, molecular, and functional events at a monoclonal level (Kubota 
and Iwabuchi, 2014; Rock, 1985; Rock and Benacerraf, 1983; Schrader 
and Clark-Lewis, 1982; White et al., 2000; Kruisbeek, 2001). Unlike 
primary T cell clones, which may eventually lose their antigen spec-
ificity over a period of time if left unstimulated, T cell hybridomas 
can maintain antigen specificity for extended periods of time be-
cause of their inherent ability to grow continuously in cultures (Rock, 
1985; White et al., 2000; Kruisbeek, 2001). 
T cell hybridomas are generated through fusion of antigen-sensi-
tized effector T cells with mouse thymoma-derived BW5147 αβ T cell 
receptor (TCR)−/− cells, leading to the expression of only the TCRs 
specific to the fused T cells (Rock, 1985; White et al., 2000; Kruisbeek, 
2001; Kubota, 2006). However, the screening procedure for antigen 
specificity is a laborious process (Rock, 1985). Generally, CD4 T cell 
hybridomas are screened based on cytokine secretion in response to 
antigen stimulations, and individual clones are then obtained mainly 
by limiting dilution cloning (LDC) (Rock, 1985; Kruisbeek, 2001; Peter-
son et al., 1999). Other methods include dispersion in soft agar, mi-
cromanipulation and flow cytometry (Rock, 1985). All these methods 
require expertise with the individual screening systems, making them 
both less practical and less desirable. For example, LDC is a labor-in-
tensive, time-consuming procedure, because the cells need to be di-
luted to a low density (2 to 3 cells/ml), followed by screening of indi-
vidual clones for their antigen specificity (Rock, 1985; Lefkovits and 
Waldmann, 1984). At least 25 such clones must be verified repeatedly 
to obtain a single antigen-specific clone, and the entire process to de-
rive antigen-specific hybridoma clones can take up to three months 
or longer, or, the fusions may need to be repeated (Rock, 1985; Kruis-
beek, 2001). Thus, there is a critical need to develop robust methods 
to derive T cell hybridoma clones quickly and efficiently in a shorter 
period of time.  
Published in Journal of Immunological Methods 426 (2015), pp. 86–94; doi: 10.1016/j.jim.2015.08.007 
Copyright © 2015 Elsevier B.V. Used by permission. 
Submitted June 30, 2015; revised August 7, 2015; accepted August 7, 2015; published online August 9, 2015. 
Versatility of using major histocompatibility complex  
class II dextramers for derivation and characterization  
of antigen-specific, autoreactive T cell hybridomas 
Bharathi Krishnan,1 Chandirasegaran Massilamany,1 Rakesh H. Basavalingappa,1  
Rajkumar A. Rajasekaran,1 Charles Kuszynski,2 Barbara Switzer,3  
Daniel A. Peterson,4 and Jay Reddy1 
1 School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583
2 Nebraska Center for Virology, University of Nebraska–Lincoln, Lincoln, NE 68583
3 College of Medicine, Dean’s Research Laboratory, University of Nebraska Medical Center, Omaha, NE 68918
4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21205
Corresponding author — J. Reddy, Room 202, Bldg VBS, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, 
Lincoln, NE 68583, USA; email nreddy2@unl.edu 
Abstract 
Antigen-specific, T cell hybridomas are useful to study the cellular, molecular and functional events, but their generation is a lengthy process. Thus, 
there is a need to develop robust methods to generate the hybridoma clones rapidly in a short period of time. To this end, we have demonstrated 
a novel approach using major histocompatibility complex (MHC) class II dextramers to generate T cell hybridomas for an autoantigen, proteolipid 
protein (PLP) 139–151. Using MHC class II dextramers assembled with PLP 139–151 as screening and sorting tools, we successfully obtained mono 
antigen-specific clones within seven to eight weeks. In conjunction with other T cell markers, dextramers permitted phenotypic characterization of 
hybridoma clones for their antigen specificity in a single step by flow cytometry. Importantly, we achieved successful fusions using dextramer+ cells 
sorted by flow cytometry as a starting population, resulting in direct identification of multiple antigen-specific clones. Characterization of selected 
clones led us to identify chemokine receptor, CCR4+ to be expressed consistently, but their cytokine-producing ability was variable. Our work pro-
vides a proof-of principle that the antigen-specific, CD4 T cell hybridoma clones can be generated directly using MHC class II dextramers. The avail-
ability of hybridoma clones that bind dextramers may serve as useful tools for various in vitro and in vivo applications. 
Keywords: T cell, hybridoma, MHC, class II dextramers, Autoreactive T cells  
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murine encephalomyelitis virus; CFA, complete Freund’s adjuvant; M.tb, Mycobacterium tuberculosis; RT, room temperature; LNCs, lymph node cells; 
IL, interleukin; FBS, fetal bovine serum; Con-A, concanavalin-A; PEG, polyethylene glycol; HAT, hypoxanthine/aminopterin/thymidine; HT, hypoxan-
thine/thymidine; 7-AAD, 7-aminoactinomycin-D; 3[H], tritiated; CCRs, chemokine receptors; PMA, phorbol 12-myristate-13 acetate; IFN, interferon; 
TNF, tumor necrosis factor.  
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We previously reported creation of the next generation of ma-
jor histocompatibility complex (MHC) class II tetramers, designated 
“dextramers,” which enabled us to detect and enumerate the pre-
cursor frequencies of autoreactive, antigen-specific CD4 T cells in a 
variety of systems (Massilamany et al., 2011a, 2014a, 2014b). Struc-
turally, dextramers contain dextran molecules (polymers of glucose), 
each carrying up to seven streptavidin moieties to which multiple 
biotinylated MHC/peptide monomers can be assembled. Thus, dex-
tramers can engage more TCRs than that could be achieved with 
tetramers (Massilamany et al., 2011a). We demonstrated that MHC 
class II dextramers exhibited greater sensitivity and specificity than 
could be achieved with MHC class II tetramers in several autoanti-
gens, such as proteolipid protein (PLP) 139–151, myelin oligoden-
drocyte glycoprotein 35–55, and cardiac myosin heavy chain-α 334–
352 (Massilamany et al., 2011a). Using PLP 139–151 dextramers as 
screening tools, we have devised a novel approach for rapidly de-
riving antigen-specific T cell hybridoma clones within 7 to 8 weeks. 
Importantly, dextramer-assisted sorting of antigen-specific clones 
allowed us to evaluate the expression of T cell markers, TCRs, and 
their vβ-usage in a single step by flow cytometry, including cytokine 
secretion and chemokine receptor expression. 
2. Materials and methods 
2.1. Ethics statement 
Five-to-six-week-old female SJL/J (H-2s) mice were procured from 
the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in 
accordance with the animal protocol guidelines of the University 
of Nebraska-Lincoln, Lincoln, NE, USA. The study was conducted 
in accordance with the National Institutes of Health guidelines for 
the use of experimental animals, and the protocols were specifi-
cally approved by the University of Nebraska-Lincoln Institutional 
Animal Care and Use Committee (permit number: A3459-01; pro-
tocol # 999). 
2.2. Peptide synthesis and immunization procedures 
PLP 139–151 (HSLGKWLGHPDKF) and Theiler’s murine encephalomy-
elitis virus (TMEV) 70–86 (WTTSQEAFSHIRIPLP) were synthesized on 
9-fluorenylmethyloxycarbonyl chemistry (Neopeptide, Cambridge, 
MA, USA). TMEV 70–86 peptide previously has been shown to bind 
MHC class II allele, IAs molecule in SJL mice (Massilamany et al., 
2010, 2011a, 2011b; Lorenz et al., 1988; Reddy et al., 2003). Thus, 
we used TMEV 70–86 as a control peptide for PLP 139–151 in all as-
says. The peptides were HPLC-purified (N90%), identity-confirmed 
by mass spectroscopy, and dissolved in sterile 1× PBS prior to use. 
Peptide emulsions involving PLP 139–151 were prepared in complete 
Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis (M.tb, 
1 mg/ml) H37RA extract (Difco Laboratories, Detroit, MI, USA), and 
administered subcutaneously into SJL mice (100 μg/mouse; n = 3) 
(Massilamany et al., 2010). At termination, animals were euthanized 
using a CO2 chamber prefilled with 2% CO2. 
2.3. Generation of MHC class II dextramers 
Dextramer reagents comprised of IAs/PLP 139–151 and IAs/TMEV 
70–86 (control) were generated as described previously (Massila-
many et al., 2011a). We have used IAs/TMEV 70–86 dextramers as 
controls to ascertain TCR-binding specificity of IAs/PLP 139–151 
dextramers, in all dextramer staining reactions (Massilamany et al., 
2011a). Briefly, the α and β constructs of IAs allele along with the 
peptide of interest were expressed together using baculovirus ex-
pression systems in SF9 insect cells (Invitrogen, Carlsbad, CA). Solu-
ble MHC class II monomers of IAs were then purified, concentrated, 
and biotinylated using biotin ligase (25 μg/10 nmol of substrate; 
Avidity, Denver, CO) (Massilamany et al., 2010, 2011a, 2011b). The 
biotinylated monomers were assembled to fluorophore conjugated 
dextran molecules (kindly provided by Immudex, Copenhagen, Den-
mark) at a molar ratio of 20:1 in 1× Tris HCl 0.05M, pH 7.2, by in-
cubating in the dark for 30 min at room temperature (RT) (Massi-
lamany et al., 2011a). The dextramer reagents were aliquoted and 
stored at 4 °C until use. 
2.4. Generation of antigen-sensitized primary T cells 
Ten days post-immunization with PLP 139–151, the draining lymph 
nodes (mandibular, axillary, inguinal, and popliteal) were collected 
and single cell suspensions were prepared. Lymph node cells (LNCs) 
were stimulated with PLP 139–151 (20 μg/ml) at a density of 5 × 106 
cells/ml for two days in clone medium (RPMI medium supplemented 
with 10% fetal bovine serum [FBS], 1 mM sodium pyruvate, 4 mML-
glutamine, 1× each of non-essential amino acids and vitamin mix-
ture, and 100 U/ml penicillin–streptomycin [Lonza, Walkersville, MD]) 
(Massilamany et al., 2010, 2011b, 2011c). After two days, the cultures 
were supplemented with clone medium containing interleukin (IL)-2 
(hereafter called IL-2 medium) and maintained for an additional two 
days. Viable lymphoblasts were harvested on day 4 and maintained 
in IL-2 medium until fusion. In some experiments, LNCs obtained 
from immunized mice were expanded with concanavalin-A (Con-A; 
1 μg/ml) at a density of 2 × 106 cells/ml for two days before fusion 
(Massilamany et al., 2014c). 
2.5. Fusion with BW5147 αβ−/− cells 
Three approaches were adopted for the generation of antigen-
specific T cell hybridoma clones (Figure 1). 
2.5.1. Approach 1: derivation of T cell hybridomas using Con-A-
stimulated T cells generated in immunized mice 
LNCs stimulated with Con-A were harvested after 48 h, and cells 
were washed twice with DMEM (1× DMEM [HyClone laboratories, 
South Logan, UT] containing 10% FBS, 1 mM sodium pyruvate, 7.5 
mM L-glutamine, 0.66 M L-arginine [Fisher BioReagents, Fair Lawn, 
NJ], 0.27 M L-asparagine [MP Biomedicals, LLC Solon, OH], 24 mM 
sodium bicarbonate [Sigma-Aldrich, St. Louis, MO], 10 mM HEPES 
[Roche Life Sciences, Indianapolis, IN], and 100 U/ml penicillin–strep-
tomycin, 0.05 mM β-mercaptoethanol [PMD Biosciences, La Jolla, 
CA]). Cells were then mixed with BW5147 αβ−/− cells at a ratio of 
1:4, washed once, and fused as described earlier (White et al., 2000; 
Kruisbeek, 2001; Canaday, 2013; Kohler et al., 1977). The tube con-
taining the cell pellet was placed in a 37 °C water bath, and 0.4 ml of 
50% polyethylene glycol (PEG) in 75 mM HEPES (Roche Life Sciences) 
was gently added in a circular motion over a 1-minute period. After 
stirring the pellet for an additional minute, a total of 10 ml of pre-
warmed DMEM with 10% FBS (hereafter called hybridoma medium) 
was delivered, 1 ml during the first minute, followed by another ml 
during the second minute, and the rest (8 ml) during the next 2 min 
(1 ml/15 s) as the mixture was gently stirred continuously (White et 
al., 2000; Kruisbeek, 2001; Canaday, 2013). After washing with hy-
bridoma medium, cells were plated in 96-well plates at a density of 
3.6 × 105 cells/ml (5 × 104 cells/140 μl/well; Figure 1). 
2.5.2. Approach 2: generation of T cell hybridomas using antigen-
stimulated T cells generated in vitro 
Viable lymphoblasts were harvested on day 4 poststimulation 
with PLP 139–151 and fused with BW5147 αβ−/− cells at a ratio of 
1:3; the cells were plated as above in 96-well plates (Figure 1). 
2.5.3. Approach 3: generation of T cell hybridomas using the MHC 
class II dextramer+ cells sorted by flow cytometry 
Viable lymphoblasts were harvested on day 4 poststimulation 
with PLP 139–151 and rested in IL-2 medium for two days. Cells 
were then stained with the dextramers (IAs/PLP 139–151 and con-
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trol dextramers) in dextramer-staining medium (IL-2 medium con-
taining 2.5% FBS, pH 7.63) at RT for 2 h (Massilamany et al., 2011a). 
After washing, PLP 139–151 dextramer-stained cells were incubated 
with a cocktail of antibodies for the predominant TCR vβs expressed 
by PLP-reactive cells (Massilamany et al., 2011d) (vβ 2, 3, 4, 6, 14 and 
17a; BD Pharmingen, San Diego, CA), and anti-CD4 (eBioscience, San 
Diego, CA). Cells were then washed and the live CD4+ dextramer+ 
vβ+ cells were sorted by flow cytometry (FACSAria, BD Biosciences, 
San Jose, CA). Cells were washed and rested in IL-2 medium for 5 
days, at which time dextramers bound to the cells were no longer 
detectable by flow cytometry, leading us to fuse these cells with 
BW5147 αβ−/− cells at a ratio of 1:5 in 0.2 ml of PEG. The fused cells 
were plated as above in 96-well plates (Figure 1). 
Regardless of the approach used, cells in 96-well plates were 
supplemented with 2× hypoxanthine/aminopterin/thymidine (HAT; 
Sigma-Aldrich) medium (DMEM/20% FBS and 2× HAT) 24 h after fu-
sion and on day 7 postfusion. Between days 10 and 12, visible clones 
were transferred from 96-well plates to 48-well plates (Figure 1). The 
cells were then gradually deprived of HAT medium by replacing with 
hypoxanthine/thymidine (HT; Sigma-Aldrich) medium (DMEM/ 20% 
FBS and 1× HT) (White et al., 2000; Kruisbeek, 2001; Canaday, 2013). 
2.6. Screening of T cell hybridomas for antigen-specificity 
and TCR vβ-usage and derivation of antigen-specific T cell 
hybridoma clones 
The T cell hybridoma clones were screened for antigen specificity 
10 to 12 days after the cells were plated in 96-well plates (Figure 
2). Pools of clones were prepared, each pool represented by cells 
obtained from 16 wells in a 48-well plate. Cells were washed and 
stained with IAs/PLP 139–151 and control dextramers in hybrid-
oma medium at RT for 1 h (Massilamany et al., 2011a). The cells 
were then stained with anti-CD3, anti-CD4, and 7-aminoactinomy-
cin-D (7-AAD) and acquired by flow cytometry. The pools positive 
for CD3, CD4, and PLP 139–151 dextramers within the live popula-
tions (7-AAD−) were analyzed using FlowJo software (Tree Star, Ash-
land, OR). The next day, individual wells from the positive pools were 
screened again by dextramer staining as above. Because each well 
could contain more than one clone with different vβs, cells in each 
well were then stained with a panel of anti-mouse TCR vβ antibod-
ies as indicated, along with anti-CD3, anti-CD4, and 7-AAD. After 
being washed and acquired by a flow cytometer, vβ+ CD3+ CD4+ 
T cell hybridoma clones were analyzed in the live (7-AAD−) popu-
lation. Finally, by using PLP 139– 151 dextramers, and vβ antibod-
ies, cells positive for both were identified. To obtain single clones, 
cells stained as above with the specific anti-TCR vβ were sorted with 
one cell per well into 96-well plates containing hybridoma medium. 
Plates were incubated until visible clones were observed, which oc-
curred between days 10 to 14 postsorting. Positive clones were grad-
ually expanded and reascertained for dextramer positivity. Clones 
were labeled appropriately and preserved in liquid nitrogen until 
further use. 
2.7. Measurement of proliferative responses 
To assess the functional responsiveness of T cell clones, we used tri-
tiated 3[H]-thymidine-incorporation assay. Briefly, hybridoma clones 
were cultured in clone medium in the presence of irradiated (3000 
rad) syngeneic LNC/splenocytes pulsed with PLP 139–151 as anti-
gen-presenting cells at a ratio of 1:5 (1 × 104:5 × 104) for 20 h. After 
pulsing with 3[H]-thymidine for 16 h, proliferative responses were 
measured as counts per minute.  
Figure 1. Approaches to the derivation of T cell hybridomas. Approach 1. LNCs from immunized mice were expanded with Con-A for two days, then 
fused with BW5147 αβ−/− cells. Approach 2. LNCs from immunized mice were stimulated with the PLP 139–151 for two days, and the cultures were 
then supplemented with IL-2medium. On day 4, viable lymphoblasts were harvested and fused with BW5147 αβ−/−cells. Approach 3. LNCs obtained 
from immunized mice were cultured with PLP 139–151 for two days and the cells were supplemented with IL-2 medium. Viable cells were harvested 
on day 4, and the cells were rested in IL-2medium for two days. On day 6, cells were stained with dextramers (IAs/PLP 139–151 and control), followed 
by a panel of selected TCR vβ antibodies; the double positive cells were then sorted by flow cytometry. After resting in IL-2 medium for 5 days, cells 
were fused. Finally, after fusions, cells were plated in 96-well plates, and, after two rounds of HAT selection, visible clones were transferred to 48-
well plates between days 10 to 12. Cells were then switched to HT medium and screened for antigen specificity using dextramers by flow cytometry. 
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2.8. Analysis of chemokine receptor expression 
The surface expression of chemokine receptors (CCRs) was analyzed 
using antibodies for CCR4, CCR5, or CCR6, anti-CD4, and 7-AAD. 
After washing, cells were acquired by flow cytometry, and percent-
ages of chemokine receptor-expressing cells were determined in 
the live (7-AAD−) population using Flow Jo software. The clones of 
antichemokine receptor antibodies used were CCR-4 (2G12), CCR-5 
(HMCCR5) and CCR-6 (29-2L17), all from BioLegend, San Diego, CA. 
2.9. Cytokine measurement 
The ability of T cell hybridomas to secrete different cytokines was 
assessed by intracellular staining (Massilamany et al., 2010, 2011c; 
Evavold et al., 1994; Nakajima et al., 2001; Wilde et al., 1992). Cells 
were stimulated with phorbol 12-myristate-13 acetate (PMA, 10 ng/
ml) and ionomycin (150 ng/ml, Sigma-Aldrich) for 5 h in the pres-
ence of 1 mM monensin (Golgi stop, BD Pharmingen). After stain-
ing with anti-CD4 and 7-AAD, cells were fixed, permeabilized, and 
stained with anti-cytokine antibodies or with the respective isotype 
controls. After washing, the cells were acquired by flow cytometry, 
and the frequencies of cytokine-producing cells were determined in 
the live (7-AAD−) CD4 population using Flow Jo software. The clones 
of anti-cytokine antibodies used were: IL-2 (JES6-5H4), interferon 
(IFN)-γ (XMG1.2), IL-4 (11B11), IL-10 (JES5-16E3), IL-17A (eBio17B7), 
and tumor necrosis factor (TNF)-α (MP6-XT22), all from eBioscience. 
3. Results and discussion 
We demonstrated the utility of using MHC class II dextramers to 
create CD4 T cell hybridomas for PLP 139–151 that induce experi-
mental autoimmune encephalomyelitis in SJL (H-2s)mice. The use of 
MHC class II dextramers offered few advantages: 1). The dextramers 
could be used as screening tools to verify the antigen specificity of 
potential clones as early as 10 to 12 days after fusion. In conjunc-
tion with other T cell markers (CD3, CD4, CD8, and TCR/vβs) the use 
of dextramers allowed us to identify antigen-specific clones by flow 
cytometry in a single step. 2). After identifying positive clones, we 
could derive mono antigen-specific clones by sorting the cells with 
one cell per well using dextramers. 3). Unlike the traditional method 
that requires a large number of antigen-sensitized T cells (up to 5 × 
107 cells), successful fusions could be achieved with as few as ~7.6 
× 105 dextramers+ cells. Overall, the time required to obtain clones 
can be cut down significantly, and all steps from immunizations to 
cloning single cells can be finished in 7–8 weeks. 
As we reported previously, dextramers were found to be helpful 
in detecting the rare antigen-specific, autoreactive CD4 T cells, which 
was not possible using tetramers, both ex vivo, and in situ within tar-
get organs such as the hearts and brains (Massilamany et al., 2011a, 
2014a, 2014b). Unlike MHC class II tetramers that contain no more 
than four biotinylated MHC/peptide complexes because only a sin-
gle streptavidin moiety is available, a large number of MHC/pep-
tide complexes (up to 20) can be assembled to each dextran back-
bone in dextramers, because multiple streptavidin moieties (6 to 7) 
are available for binding the biotinylated MHC molecules (Massila-
many et al., 2011a; Batard et al., 2006). As a result, large aggregates 
of MHC/peptide complexes can be generated through dextramers, 
leading to enhanced avidity for binding to T cells by engaging mul-
tiple TCRs. Thus, using dextramers could increase detection sensi-
tivity by at least 5-fold, as compared with use of tetramers (Massi-
lamany et al., 2011a). Although derivation of T cell hybridomas for 
PLP 139–151 has been reported previously (Donermeyer et al., 1995; 
Figure 2. Screening of T cell hybridomas for antigen specificity. Pools of 
cells representing 16 wells in 48-well plates were prepared, and the cells 
were stained with IAs/MHC class II dextramers (PLP 139–151 and con-
trol). Pools that were positive for PLP 139–151 dextramers were identi-
fied, then individual wells containing the dextramer+ cells were identi-
fied. Cells in these wells were tested for both TCR vβs and dextramers; 
the double-positive cells were sorted by flow cytometry with one cell 
per well; and their antigen-specificity was reconfirmed.  
Table 1. Evaluation of TCR vβ-usage in PLP 139–151 dextramer+ CD4+ T cell hybridoma clones. 
Well      Dextramer      Panel of TCR vβ antibodies used 
ID    staining vβ2 vβ3 vβ4 vβ5.1/5.2 vβ6 vβ7 vβ8.1/8.2 vβ8.3 vβ9 vβ10b vβ11 vβ12 vβ13 vβ14 vβ17a 
A9 + − − − − − − − − − − − − − − + 
A17 + + − + − − − − − − − − − − − + 
A31 + + − − − − − − − − − − − − − − 
D19 + + − + − − − − − − − − − − + + 
D26 + + − − − − − − − − − − − − − + 
E48 + + − + − − − − − − − − − − − + 
H2 + + − + − − − − − − − − − − − − 
H15 + + − + − − − − − − − − − − − + 
I14 + − + − − + − − − − − − − − − + 
I29 + + − − − − − − − − − − − − − − 
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Kuchroo et al., 1994), we took advantage of the availability of dext-
ramer reagents for this antigen to demonstrate their utility for de-
riving antigen-specific T cell hybridomas quickly and efficiently, by 
exploring three different approaches (Figure 1). 
3.1. Approach 1: derivation of T cell hybridomas using Con-A-
stimulated T cells generated in immunized mice 
Con-A is traditionally used as a mitogen to stimulate unprimed poly-
clonal T cell populations that permit assessment of the overall im-
munocompetence in physiological and clinical conditions (Stone et 
al., 2009; Kruisbeek et al., 2004; Krammer et al., 1982). Here, we used 
this reagent to expand antigen-sensitized T cells ex vivo with an ex-
pectation that they may get enriched upon activation, thus allowing 
their availability to be more in number for fusions. We used LNCs 
sensitized with PLP 139–151 from immunized mice, and, after expan-
sion with Con-A for two days, cells were fused, expecting that viable 
clones could be directly screened by dextramers for their antigen 
specificity. The fused cells were plated in ten 96-well plates (10 × 96 
= 960 wells), and, after 12 days, successful fusions as indicated by 
viability/growth of cells were noted in 30% of the wells (288/960 × 
100). We then made 18 pools, each representing cells from 16 wells 
for staining with PLP 139–151 dextramers (Figure 2). Contrary to our 
expectations, we did not detect the pools positive for staining with 
PLP 139–151 dextramers. Such an outcome was not surprising, how-
ever, given the low frequencies of antigen-sensitized T cells pres-
ent in the ex vivo LNCs populations (Jenkins and Moon, 2012).We 
had previously determined the frequency of PLP 139–151-specific 
cells to be 0.12% of total CD4 T cells in immunized SJL mice (Mas-
silamany et al., 2011a). We had predicted that Con-A-stimulation 
might sufficiently facilitate the expansion of antigen-specific T cells 
to allow us to obtain a few clones, but this was not the case. Alter-
natively, this approach may still prove to be successful if CD4 T cells 
enriched from immunized animals are used as a starting population 
for fusions, but we did not investigate this possibility. 
3.2. Approach 2: generation of T cell hybridomas using 
antigen-stimulated T cells generated in vitro 
Here, we fused the effector T cells generated from PLP 139–151 im-
munized mice with BW5147 αβ−/− cells (Rock, 1985; White et al., 
2000; Kruisbeek, 2001). LNCs were obtained from immunized SJL 
mice, and after stimulating the cells with PLP 139–151 and resting 
them in IL-2 medium, viable lymphoblasts were used for fusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure 1). We used dextramer reagents (IAs/PLP 139–151, and con-
trol) for screening and cloning antigen-specific hybridomas as a 
novel strategy in a step-wise fashion (Figure 2). 
3.2.1. Step 1 
To generate PLP 139–151-specific hybridomas, eight 96-well 
plates were plated with the fused cells (8 × 96 = 768 wells). Suc-
cessful fusions, indicated by viability/growth of cells, were noted in 
62.5% of the wells (480/768 × 100). We then made 30 pools, each 
consisting of cells from 16 wells, and tested them for staining with 
PLP 139–151 dextramers, where TMEV 70–86 dextramers were used 
as controls. We randomly picked 8 pools that were positive for PLP 
139–151 dextramers. Dextramer staining was then repeated individ-
ually using cells from each of the 128 wells (8 pools × 16). This anal-
ysis led us to identify at least 10wells that were positive for PLP 139–
151 dextramers (10/128 × 100 = 7.8%) (Table 1). 
3.2.2. Step 2 
In this step, cells in the dextramer+ wells were screened for TCR 
vβ-usage. Since, dextramer+ cells in each well could contain more 
than one clone, potentially with different vβ-usage, we decided to 
first screen each of the 10 wells of PLP 139–151-dextramer+ clones 
with a panel of vβ antibodies. The selected vβ panels were based 
on the published literature and our own data (Massilamany et al., 
Figure 3. Generation of antigen-specific, single cell clones by flow cytometry. To obtain single cell clones, cells were stained with IAs/dextramers (PLP 
139–151 and control), CD4 and vβ17a or vβ2 antibodies and 7-AAD. Through flow cytometric analysis, PLP 139–151 dextramer+ vβ+ cells were sorted 
with one cell per well, and after expansion, their antigen-specificity was reconfirmed by dextramer staining as described above.  
Table 2. Derivation of PLP 139–151-specific hybridoma clones using PLP 
139–151 dextramer+ cells sorted by flow cytometry as the starting pop-
ulation for fusions. 
               
Dextramer
               Panel of TCR vβ antibodies used 
Well ID staining vβ2 vβ3 vβ4 vβ6 vβ14 vβ17a
A3 + + − − − − +
A9 + + − + − − +
A13 + + − − − + −
A18 + − − + − − +
A22 + − − + − + −
A36 + + − − + − −
A38 + − − + − − −
A47 + − − − − − −
B2 + − − + − − +
B11 + − − + − − +
B12 + + − − − − +
B13 + − − + − − +
B16 + + − + + − −
B27 + − − − − − +
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2011c, 2011d; Kuchroo et al., 1992; Whitham et al., 1993). Through 
these analyses we identified wells showing positive staining for up 
to six vβs for PLP 139–151 (vβ2, vβ3, vβ4, vβ6, vβ14 and vβ17a; Ta-
ble 1). Of note, for analysis of vβ-expressing dextramer+ cells, it was 
critical to stain with dextramers first, followed by staining with vβ 
antibodies (Massilamany et al., 2011d). Staining with the above re-
agents in reverse order allows detection of only vβ+ cells, and as 
such, the proportion of dextramer+ cells can be absent or signif-
icantly reduced, indicating that vβ-antibodies can sterically hinder 
dextramers from binding to TCRs. 
3.2.3. Step 3 
After identifying the wells positive for both dextramers and spe-
cific vβs, we sought to provide a proof-of principle that single cell 
clones can be obtained by flow cytometric sorting of dextramer+ 
cells. To this end, we selected two wells (A9 and D26; Table 1) and 
sorted the cells positive for PLP 139–151 dextramers and anti-vβ17a 
or anti-vβ2 respectively with a single cell per well into one 96-well 
plate for each. We obtained a total of 31 viable clones, and rescreen-
ing of these by dextramer staining led us to identify at least ten 
clones to be highly positive for PLP 139–151 dextramers (Figure 3). 
3.3. Approach 3: generation of T cell hybridomas using the 
MHC class II dextramer+ cells sorted by flow cytometry 
In this approach, we asked whether dextramer+ T cells could be 
used as a starting population for fusing the cells, expecting the dex-
tramer+ clones to be antigen specific, thus avoiding the multi-step 
procedure described in approach 2. We addressed this question 
by sorting the antigen-specific CD4 T cells from LNC cultures de-
Figure 4. Phenotypic and functional characterization of selected T cell hybridomas. (a) Surface markers. Three T cell hybridoma clones, specific for 
PLP 139–151were selected, and expression of CD3, CD4, CD8, and TCRs was characterized by flow cytometry. (b) Antigen specificity. Antigen spec-
ificity of the selected clones was tested by dextramer staining, and proliferative responses as evaluated by flow cytometry and 3[H]-thymidine incor-
poration assay, respectively. The experimental details are as described in the Materials and methods section. PLP 139–151: specific antigen; TMEV 
70–86: control antigen. Representative data from three to four individual experiments are shown.   
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rived from SJL mice immunized with PLP 139–151. For sorting PLP 
139–151-specific cells, we used PLP 139–151 or control dextramers, 
anti-CD4, and a mixture of anti-vβs (vβ2, 3, 4, 6, 14 and 17a). We 
sorted a total of 7.6 × 105 dextramer+ vβ+ cells by flow cytometry, 
and after resting the cells in IL-2-medium for 5 days, the cells were 
fused with BW5147 αβ−/− cells, followed by plating in one 96-well 
plate. We noted successful fusions as indicated by viable clones in 
78 wells (78 / 96 × 100 = 81.3%). A total of 16 pools, each repre-
sented by cells from 3 to 5 wells, were then stained with PLP 139–
151 dextramers, leading us to identify 10 positive pools. Cells from 
each of 50 wells (10 pools × 5) were then screened for staining with 
dextramers leading us to identify at least 14 wells that were positive 
for dextramers (14/50 × 100 = 28%), which were then examined for 
vβ-expression using selected TCR vβ antibodies, as shown in Table 
2. Expectedly, cells in each well showed positive staining for more 
than one vβ, suggesting the presence of multiple clones in a given 
well (Table 2). Thus, we have provided a proof of principle that an-
tigen-specific T cell hybridoma clones can be obtained using dext-
ramer+ cells as a starting population for fusions. 
Overall, the relative successful cell-fusion frequencies obtained 
from all the three approaches were in the order of approach 3 
(81.3%) followed by approach 2 (62.5%), and approach 1 (30%). 
Similarly, screening of these fusions also led us to identify 28% of 
wells to contain antigen (PLP 139–151)-specific hybridoma clones 
with approach 3 as opposed to 7.8% with approach 2, and none 
with approach 1. 
After generating the T cell hybridomas for PLP 139–151, we 
sought to characterize their phenotypes. We selected three clones 
(A9/17, A9/ 23, and A9/24; Figure 3); all of them showed the expres-
sion of CD3, CD4 and TCR (Figure 4a). We then evaluated antigen 
Figure 5. Characterization of T cell hybridomas based on the expression of chemokine receptors and cytokines. Three T cell hybridoma clones, spe-
cific to PLP 139–151 were evaluated for surface expression of chemokine receptors and cytokine secretion by intracellular staining as described in 
the Materials and methods section. Top panel (a) indicates the expression of CCR4, and bottom panel (b) represents cytokine-producing CD4+ cells. 
Representative data from three individual experiments are shown.    
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specificity based on dextramer staining and proliferative responses. 
Expectedly, all PLP 139–151-specific clones could be stained with the 
corresponding dextramers but not with control dextramers (Figure 
4b: top panel). Next, we asked whether PLP 139–151-specific clones 
can functionally respond to antigens. Using 3[H]-thymidine incor-
poration assay, it was clear that all PLP 139–151-specific clones re-
sponded to PLP 139–151 stimulation, but the net outcome was re-
duced proliferative response likely due to cell death as reported by 
others (Donermeyer et al., 1995; Shi et al., 1989, 1990; Waldner et al., 
2000), which occurred only with PLP 139–151 but not with the con-
trol antigen (Figure 4b: bottom panel). Thus, we identified function-
ally responsive clones for PLP 139–151. Finally, we asked whether 
the functionalities of antigen-specific T cell hybridomas can be dis-
tinguished based on chemokine receptor expression and cytokine 
synthesis (Figure 5). By testing for chemokine receptors CCR4, CCR5, 
and CCR6 as the putative markers for Th2, Th1, and Th17 pheno-
types (Islam and Luster, 2012; Wu et al., 2001), respectively, only 
CCR4 was found to be present in all PLP 139– 151-specific clones 
(Figure 5a). However, testing for their cytokine producing ability by 
intracellular staining revealed that one PLP 139– 151-specific clone 
(A9/23) was positive for IL-2 and IL-4, whereas two other clones 
(A9/17 and A9/24) showed only marginal production of IL-2 (Figure 
5b). None of the clones showed any detectable staining for other 
cytokines (proinflammatory cytokines IFN-γ, IL-17A, and TNF-α and 
the anti-inflammatory cytokine IL-10; data not shown) indicating 
that the cytokine-producing ability of T cell hybridomas is largely 
restricted to T cell growth factors. Similar observations have been 
made with T cell hybridoma clones specific to various other antigens 
(Rock, 1985; Hagiwara et al., 1988). 
4. Conclusions 
In summary, we have demonstrated the utility of MHC class II dex-
tramers for cloning antigen-specific CD4 T cell hybridomas using 
PLP 139–151 as an autoantigen. We have previously reported that 
dextramers are expected to bind T cells bearing high-affinity TCRs 
and therefore propose that the hybridoma clones obtained by using 
dextramers might carry such TCRs. However, in spite of enhanced 
detection sensitivity, dextramers cannot detect the complete rep-
ertoire of antigen-specific T cells as we previously demonstrated 
(Massilamany et al., 2011a). Thus, we cannot conclude that dextra-
mer− clones are not antigen-specific, and the clones possibly ex-
pressing the low-affinity TCRs might be undetected by dextramers. 
Nonetheless, if MHC class II dextramer-bound T cells are to be in-
terpreted as T cells bearing high affinity TCRs, then the availability 
of dextramer-detectable hybridoma clones can serve as useful tools 
for various applications, such as screening peptide libraries to iden-
tify antigenic epitopes, epitope mimics, altered peptide ligands, and 
chemical analogues of activating ligands; studies related to antigen 
processing and presentation pathways; production of TCR-specific 
monoclonal antibodies; in vivo tracking of antigen-specific T cells; 
and other molecular and functional studies that involve interactions 
with TCRs (Rock, 1985; Canaday et al., 2003; Depta et al., 2004; Green 
et al., 1994; Zumla et al., 1992). One caveat to keep in mind about 
dextramer-assisted generation of T cell hybridomas is that the avail-
ability of MHC dextramers for antigens of interest is absolutely crit-
ical, but their generation per se may be a time-consuming process. 
Should the dextramer reagents be made available, then derivation 
of T cell hybridomas can be accomplished rapidly in a limited time-
frame of 7–8 weeks. 
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